Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Friday, August 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has announced the publication of mature Phase 1b results for its treatment combining botensilimab (BOT) and balstilimab (BAL) in patients with microsatellite-stable metastatic colorectal cancer. The study involved 123 heavily pre-treated patients and highlighted the distinct immune-priming mechanism of the treatment. This peer-reviewed publication marks a significant advancement in immuno-oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Publication of mature Phase 1b results is a significant milestone.
  • Demonstrated durable survival in MSS metastatic colorectal cancer.
  • Potential for BOT and BAL combination to enhance treatment efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
6.2%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
Botensilimab
Phase 1 · Pancreatic Cancer Metastatic

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The manuscript,

Frequently Asked Questions

What is the focus of Agenus' recent publication?

The publication focuses on the Phase 1b results of BOT and BAL in MSS metastatic colorectal cancer.

How many patients were involved in the study?

The study involved 123 heavily pre-treated patients.

What type of cancer was targeted in the research?

The research targeted microsatellite-stable metastatic colorectal cancer.

What is the significance of the publication?

The publication highlights the durable survival linked to the immune-priming mechanism of BOT and BAL.

ShareAdd on Google
Tags: AGEN Viatris Investor Conferences Healthcare Agenus botensilimab balstilimab mCRC immuno-oncology
Last updated: Aug 28, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~1 mo
High dilution risk
Lead asset
BotensilimabPhase 1
Pancreatic Cancer Metastatic →

Catalyst track record

+52%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →